Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases

Merouane Bencherif, Patrick M. Lippiello, Rudolf Lucas, Mario B. Marrero

Research output: Contribution to journalReview article

114 Citations (Scopus)

Abstract

In recent years the etiopathology of a number of debilitating diseases such as type 2 diabetes, arthritis, atherosclerosis, psoriasis, asthma, cystic fibrosis, sepsis, and ulcerative colitis has increasingly been linked to runaway cytokine-mediated inflammation. Cytokine-based therapeutic agents play a major role in the treatment of these diseases. However, the temporospatial changes in various cytokines are still poorly understood and attempts to date have focused on the inhibition of specific cytokines such as TNF-α. As an alternative approach, a number of preclinical studies have confirmed the therapeutic potential of targeting alpha7 nicotinic acetylcholine receptor-mediated anti-inflammatory effects through modulation of proinflammatory cytokines. This "cholinergic anti-inflammatory pathway" modulates the immune system through cholinergic mechanisms that act on alpha7 receptors expressed on macrophages and immune cells. If the preclinical findings translate into human efficacy this approach could potentially provide new therapies for treating a broad array of intractable diseases and conditions with inflammatory components.

Original languageEnglish (US)
Pages (from-to)931-949
Number of pages19
JournalCellular and Molecular Life Sciences
Volume68
Issue number6
DOIs
StatePublished - Mar 1 2011

Fingerprint

Nicotinic Receptors
Cytokines
Inflammation
Cholinergic Agents
alpha7 Nicotinic Acetylcholine Receptor
Anti-Inflammatory Agents
Homeless Youth
Therapeutics
Ulcerative Colitis
Psoriasis
Cystic Fibrosis
Type 2 Diabetes Mellitus
Arthritis
Immune System
Sepsis
Atherosclerosis
Asthma
Macrophages

Keywords

  • Acetylcholine
  • Alpha7
  • Diabetes
  • Inflammation
  • Nicotinic

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Pharmacology
  • Cellular and Molecular Neuroscience
  • Cell Biology

Cite this

Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases. / Bencherif, Merouane; Lippiello, Patrick M.; Lucas, Rudolf; Marrero, Mario B.

In: Cellular and Molecular Life Sciences, Vol. 68, No. 6, 01.03.2011, p. 931-949.

Research output: Contribution to journalReview article

Bencherif, Merouane ; Lippiello, Patrick M. ; Lucas, Rudolf ; Marrero, Mario B. / Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases. In: Cellular and Molecular Life Sciences. 2011 ; Vol. 68, No. 6. pp. 931-949.
@article{b66ec85fe4de4b88ac585ddc25f23e09,
title = "Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases",
abstract = "In recent years the etiopathology of a number of debilitating diseases such as type 2 diabetes, arthritis, atherosclerosis, psoriasis, asthma, cystic fibrosis, sepsis, and ulcerative colitis has increasingly been linked to runaway cytokine-mediated inflammation. Cytokine-based therapeutic agents play a major role in the treatment of these diseases. However, the temporospatial changes in various cytokines are still poorly understood and attempts to date have focused on the inhibition of specific cytokines such as TNF-α. As an alternative approach, a number of preclinical studies have confirmed the therapeutic potential of targeting alpha7 nicotinic acetylcholine receptor-mediated anti-inflammatory effects through modulation of proinflammatory cytokines. This {"}cholinergic anti-inflammatory pathway{"} modulates the immune system through cholinergic mechanisms that act on alpha7 receptors expressed on macrophages and immune cells. If the preclinical findings translate into human efficacy this approach could potentially provide new therapies for treating a broad array of intractable diseases and conditions with inflammatory components.",
keywords = "Acetylcholine, Alpha7, Diabetes, Inflammation, Nicotinic",
author = "Merouane Bencherif and Lippiello, {Patrick M.} and Rudolf Lucas and Marrero, {Mario B.}",
year = "2011",
month = "3",
day = "1",
doi = "10.1007/s00018-010-0525-1",
language = "English (US)",
volume = "68",
pages = "931--949",
journal = "Cellular and Molecular Life Sciences",
issn = "1420-682X",
publisher = "Birkhauser Verlag Basel",
number = "6",

}

TY - JOUR

T1 - Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases

AU - Bencherif, Merouane

AU - Lippiello, Patrick M.

AU - Lucas, Rudolf

AU - Marrero, Mario B.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - In recent years the etiopathology of a number of debilitating diseases such as type 2 diabetes, arthritis, atherosclerosis, psoriasis, asthma, cystic fibrosis, sepsis, and ulcerative colitis has increasingly been linked to runaway cytokine-mediated inflammation. Cytokine-based therapeutic agents play a major role in the treatment of these diseases. However, the temporospatial changes in various cytokines are still poorly understood and attempts to date have focused on the inhibition of specific cytokines such as TNF-α. As an alternative approach, a number of preclinical studies have confirmed the therapeutic potential of targeting alpha7 nicotinic acetylcholine receptor-mediated anti-inflammatory effects through modulation of proinflammatory cytokines. This "cholinergic anti-inflammatory pathway" modulates the immune system through cholinergic mechanisms that act on alpha7 receptors expressed on macrophages and immune cells. If the preclinical findings translate into human efficacy this approach could potentially provide new therapies for treating a broad array of intractable diseases and conditions with inflammatory components.

AB - In recent years the etiopathology of a number of debilitating diseases such as type 2 diabetes, arthritis, atherosclerosis, psoriasis, asthma, cystic fibrosis, sepsis, and ulcerative colitis has increasingly been linked to runaway cytokine-mediated inflammation. Cytokine-based therapeutic agents play a major role in the treatment of these diseases. However, the temporospatial changes in various cytokines are still poorly understood and attempts to date have focused on the inhibition of specific cytokines such as TNF-α. As an alternative approach, a number of preclinical studies have confirmed the therapeutic potential of targeting alpha7 nicotinic acetylcholine receptor-mediated anti-inflammatory effects through modulation of proinflammatory cytokines. This "cholinergic anti-inflammatory pathway" modulates the immune system through cholinergic mechanisms that act on alpha7 receptors expressed on macrophages and immune cells. If the preclinical findings translate into human efficacy this approach could potentially provide new therapies for treating a broad array of intractable diseases and conditions with inflammatory components.

KW - Acetylcholine

KW - Alpha7

KW - Diabetes

KW - Inflammation

KW - Nicotinic

UR - http://www.scopus.com/inward/record.url?scp=79953703686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953703686&partnerID=8YFLogxK

U2 - 10.1007/s00018-010-0525-1

DO - 10.1007/s00018-010-0525-1

M3 - Review article

C2 - 20953658

AN - SCOPUS:79953703686

VL - 68

SP - 931

EP - 949

JO - Cellular and Molecular Life Sciences

JF - Cellular and Molecular Life Sciences

SN - 1420-682X

IS - 6

ER -